Epidermal growth factor receptor: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: {{subpages}} In biochemistry, '''epidermal growth factor receptor 2''' ('''HER2''', '''HER-2''', '''HER2/neu''') is a cell surface receptor that is a "involved in regulation of cel...) |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[biochemistry]], '''epidermal growth factor receptor 2''' (''' | In [[biochemistry]], '''epidermal growth factor receptor 2''' ('''EGFR''', '''erbB-1''', '''HER1''', '''HER-1''') is a [[cell surface receptor]] that is a "involved in regulation of cell growth and differentiation. It is specific for [[epidermal growth factor]] and EGF related peptides including [[transforming growth factor alpha]], amphiregulin, and heparin-binding EGF-like growth factor. The binding of ligand to the receptor causes activation of its intrinsic [[tyrosine kinase]] activity and rapid internalization of the receptor-ligand complex into the cell."<ref>{{MeSH}}</ref> | ||
[[Cetuximab]] (IMC-C225) is a recombinant, human/mouse chimeric [[monoclonal antibody]] that binds to EGFR and may treat head and neck cancers, [[colorectal cancer]], and non-small cell [[lung cancer]] in patients who do not have mutations in the KRAS gene.<ref name="pmid19339720">{{cite journal| author=Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al.| title=Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 14 | pages= 1408-17 | pmid=19339720 | [[Cetuximab]] (IMC-C225) is a recombinant, human/mouse chimeric [[monoclonal antibody]] that binds to EGFR and may treat head and neck cancers, [[colorectal cancer]], and non-small cell [[lung cancer]] in patients who do not have mutations in the KRAS gene.<ref name="pmid19339720">{{cite journal| author=Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al.| title=Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 14 | pages= 1408-17 | pmid=19339720 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19339720 | doi=10.1056/NEJMoa0805019 }} </ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=19339720 | doi=10.1056/NEJMoa0805019 }} </ref> Panitumumab is also a [[monoclonal antibody]] that binds to EGFR and may treat [[colorectal cancer]]. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Latest revision as of 06:56, 1 May 2010
In biochemistry, epidermal growth factor receptor 2 (EGFR, erbB-1, HER1, HER-1) is a cell surface receptor that is a "involved in regulation of cell growth and differentiation. It is specific for epidermal growth factor and EGF related peptides including transforming growth factor alpha, amphiregulin, and heparin-binding EGF-like growth factor. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell."[1]
Cetuximab (IMC-C225) is a recombinant, human/mouse chimeric monoclonal antibody that binds to EGFR and may treat head and neck cancers, colorectal cancer, and non-small cell lung cancer in patients who do not have mutations in the KRAS gene.[2] Panitumumab is also a monoclonal antibody that binds to EGFR and may treat colorectal cancer.
References
- ↑ Anonymous (2024), Epidermal growth factor receptor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al. (2009). "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.". N Engl J Med 360 (14): 1408-17. DOI:10.1056/NEJMoa0805019. PMID 19339720. Research Blogging.